For maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients
NOW APPROVED
Introducing Ohtuvayre™ (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase (PDE) 3 and PDE4—a novel approach to bronchodilation and
non-steroidal anti-inflammation.1,2
Proven effective alone or in combination with maintenance therapy in persistently symptomatic patients.1 Oral inhalation, twice daily in the morning and evening.1
For maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients
NOW APPROVEDIntroducing Ohtuvayre™ (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase (PDE) 3 and PDE4—a novel approach to bronchodilation and non-steroidal anti-inflammation.1,2
Proven effective alone or in combination with maintenance therapy in persistently symptomatic patients.1 Oral inhalation, twice daily in the morning and evening.1
Coming soon!
Prescribe Ohtuvayre (ensifentrine) exclusively through Verona Pathway Plus™
Available 3rd quarter,2024—for detailed information on filling a prescription, click or call 833-372-8492
Verona Pathway Plus assists you, your Patients, and their Caregivers in navigating access and resources throughout treatment.
![Verona Pathway Plus logo](https://ohtuvayrehcp.com/wp-content/themes/ohtuvayrehcp/assets/images/vernona-pathway-plus.png)
Coming soon!
![Verona Pathway Plus logo](https://ohtuvayrehcp.com/wp-content/themes/ohtuvayrehcp/assets/images/vernona-pathway-plus-mobile.png)
Prescribe Ohtuvayre (ensifentrine) exclusively through Verona Pathway Plus™
Available 3rd quarter,2024—for detailed information on filling a prescription, click or call 833-372-8492